Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

One-Year Follow-up on Liraglutide Treatment for Prediabetes and Overweight/Obesity in Clozapine- or Olanzapine-Treated Patients

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. The association between depressive mood and ischemic heart disease: a twin study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Lithium as the drug of choice for maintenance treatment in bipolar disorder

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Genome-wide gene expression in a pharmacological hormonal transition model and its relation to depressive symptoms

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Alcohol and delirium tremens: effects of average number of drinks per day and beverage type

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Parental alcohol use disorder with and without other mental disorders and offspring alcohol use disorder

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Epicardial adipose tissue predicts incident cardiovascular disease and mortality in patients with type 2 diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion-A Review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. An echocardiographic substrate for dyspnea identifies high risk patients with type 2 diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Epicardial and pericardial adipose tissues are associated with reduced diastolic and systolic function in type 2 diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

OBJECTIVE: Treatment with most antipsychotics is associated with an increased risk of weight gain and metabolic disturbances. In a randomized trial, we previously demonstrated that 16 weeks of glucagon-like peptide-1 receptor agonist liraglutide treatment vs. placebo significantly reduced glucometabolic disturbances and body weight in prediabetic, overweight/obese schizophrenia-spectrum disorder patients treated with clozapine or olanzapine. The aim of this study was to investigate whether the beneficial effects of the 16-week intervention were sustained beyond the intervention period.

METHOD: One year after completion of the intervention, we investigated changes in body weight, fasting glucose, glycated hemoglobin, C-peptide and lipids comparing one-year follow-up levels to end of treatment (week 16) and baseline (week 0) levels.

RESULTS: From end of treatment to the one-year follow-up, body weight had increased in the liraglutide-treated group. However, compared to baseline levels, the placebo-subtracted body weight loss remained significantly reduced (-3.8 kg, 95% CI: -7.3 to -0.2, P = 0.04). Fasting glucose, glycated hemoglobin, C-peptide and lipids had each returned to baseline levels one year after stopping liraglutide.

CONCLUSION: The body weight reduction during 16 weeks of liraglutide treatment was partially sustained one year after the intervention was completed. However, the improvements in other metabolic parameters returned to baseline levels. This article is protected by copyright. All rights reserved.

OriginalsprogEngelsk
TidsskriftActa Psychiatrica Scandinavica
Vol/bind139
Udgave nummer1
Sider (fra-til)26-36
Antal sider11
ISSN0001-690X
DOI
StatusUdgivet - jan. 2019

ID: 55633064